Cytokine Release Syndrome: Symptoms, Treatment, and COVID-19

Note: This article is for educational purposes only and should not replace medical advice. Cytokine release syndrome can become serious quickly, so anyone with concerning symptoms after immunotherapy, infection, or COVID-19 should contact a healthcare professional immediately.

What Is Cytokine Release Syndrome?

Cytokine release syndrome, often shortened to CRS, is an intense inflammatory reaction that happens when the immune system releases a large amount of cytokines into the bloodstream too quickly. Cytokines are small signaling proteins that help immune cells communicate. On a normal day, they are like helpful group-chat messages: “Virus spotted,” “send backup,” “calm down,” and “repair crew needed.” But during cytokine release syndrome, the group chat becomes 3,000 unread messages, everyone is shouting, and the body starts reacting as if every room in the house is on fire.

CRS is most often discussed in cancer care because it can occur after certain powerful immunotherapies, especially CAR T-cell therapy and some monoclonal antibody or bispecific antibody treatments. These treatments are designed to wake up the immune system and point it toward cancer cells. That is the good news. The tricky part is that a suddenly activated immune system can sometimes overshoot the target and cause body-wide inflammation.

CRS can also occur with infections and other immune-triggering conditions. During the COVID-19 pandemic, many people heard the phrase “cytokine storm,” which describes a severe, uncontrolled inflammatory response. CRS and cytokine storm are related concepts, but they are not always identical. In cancer immunotherapy, CRS has specific grading systems and treatment protocols. In COVID-19, doctors often talk about hyperinflammation, immune dysregulation, or cytokine storm-like illness because the process may overlap with CRS but involve additional factors such as viral injury, blood clotting, lung inflammation, and organ stress.

Why Cytokines Matter

Cytokines are not villains. In fact, without them, the immune system would be like a fire department with no radios. They help white blood cells recognize threats, coordinate inflammation, attack infected or abnormal cells, and begin healing. Problems arise when cytokines are released in excessive amounts or at the wrong time.

In CRS, inflammatory cytokines such as interleukin-6, interleukin-1, interferon-gamma, and others may surge. This can affect blood vessels, lungs, heart rhythm, blood pressure, kidneys, liver, brain, and clotting pathways. In mild cases, CRS may feel like a bad flu. In severe cases, it can cause dangerously low blood pressure, low oxygen levels, confusion, shock, and multiple organ dysfunction. In other words, it can go from “I feel awful” to “this needs an ICU team” faster than anyone would like.

Common Causes and Triggers of Cytokine Release Syndrome

CAR T-Cell Therapy

CAR T-cell therapy is one of the best-known causes of CRS. In this treatment, a patient’s T cells are collected, genetically modified to recognize cancer cells, multiplied, and infused back into the body. When these engineered cells find their target, they can multiply and attack aggressively. This immune activation can produce a wave of cytokines.

CRS after CAR T-cell therapy often begins within the first few days after infusion, although timing can vary depending on the treatment, cancer type, disease burden, and patient factors. Many cancer centers closely monitor patients during this high-risk window because early recognition makes treatment much more effective.

Bispecific Antibodies and Other Immunotherapies

Bispecific antibodies are another modern cancer treatment that can trigger CRS. These medicines help immune cells connect with cancer cells, almost like introducing two people at a party and saying, “You two need to talk.” Because they activate immune attack, they can also cause inflammatory side effects. Some treatment plans use step-up dosing, premedication, and close monitoring to reduce risk.

Infections, Including COVID-19

Severe infections can also provoke uncontrolled inflammation. COVID-19 brought this issue into public conversation because some hospitalized patients developed severe lung inflammation, high inflammatory markers, low oxygen levels, blood clotting problems, and organ injury. In these cases, the immune response can become part of the problem, not just part of the solution.

That does not mean every fever with COVID-19 is cytokine release syndrome. Most COVID-19 cases do not involve a true cytokine storm. However, in severe or critical COVID-19, especially when oxygen needs rise and inflammatory markers increase, doctors may consider treatments that calm harmful inflammation while still supporting the body’s fight against infection.

Symptoms of Cytokine Release Syndrome

CRS can look different from person to person, but fever is one of the hallmark signs. In modern grading systems for immune-effector-cell therapies, fever is central to diagnosis, while severity is largely determined by blood pressure problems, oxygen needs, and organ involvement.

Mild to Moderate Symptoms

Early CRS may resemble the flu, which is inconvenient because the flu already has a reputation for making people feel like they were hit by a slow-moving truck. Mild to moderate symptoms may include:

• Fever or chills
• Fatigue or weakness
• Headache
• Muscle aches or joint pain
• Nausea, vomiting, or diarrhea
• Loss of appetite
• Rash
• Fast heartbeat
• Low-grade dizziness or lightheadedness

Severe Symptoms

Severe CRS requires urgent medical care. Symptoms and warning signs may include:

• Low blood pressure
• Shortness of breath or low oxygen levels
• Confusion, agitation, or extreme sleepiness
• Chest pain or irregular heartbeat
• Severe swelling from capillary leak
• Reduced urination, which may suggest kidney stress
• Abnormal bleeding or clotting problems
• Liver enzyme abnormalities
• Shock or multiple organ dysfunction

Patients receiving CAR T-cell therapy or similar treatments are usually given clear instructions about when to call their oncology team. This is one set of instructions worth reading before symptoms start, not while trying to Google “fever after immunotherapy” at 2:13 a.m. with one eye open.

How Doctors Diagnose CRS

There is no single “yes or no” test for cytokine release syndrome. Diagnosis depends on the clinical picture: recent immunotherapy or infection, fever, blood pressure changes, oxygen levels, organ function, and lab findings. Doctors also need to rule out other dangerous conditions, especially infection and sepsis, because these can look very similar.

Common tests may include complete blood count, liver and kidney function tests, C-reactive protein, ferritin, coagulation studies, blood cultures, chest imaging, oxygen monitoring, and sometimes cytokine measurements. In COVID-19, doctors may also evaluate oxygen needs, chest imaging, viral testing, inflammatory markers, clotting risk, and signs of bacterial co-infection.

The challenge is that inflammation is not a neat little box. Fever, fast heart rate, low blood pressure, and abnormal labs can occur in CRS, sepsis, severe COVID-19, allergic reactions, tumor lysis syndrome, and other complications. That is why context matters. A fever two days after CAR T-cell infusion means something very different from a fever after eating questionable gas-station sushi, though both deserve respect.

How CRS Severity Is Graded

In cancer immunotherapy, clinicians often use standardized grading systems to classify CRS. The American Society for Transplantation and Cellular Therapy grading approach focuses heavily on fever, hypotension, and hypoxia. In simple terms, doctors ask: Is there a fever? Is blood pressure dropping? Does the patient need oxygen? Are organs being affected?

Mild CRS may involve fever without low blood pressure or oxygen problems. More serious CRS may require IV fluids, oxygen support, medications to raise blood pressure, ICU monitoring, or mechanical ventilation. Grading helps the care team choose treatment and communicate clearly. In a hospital, “a little worse” is not precise enough. A standardized grade tells everyone how urgently the situation is changing.

Treatment for Cytokine Release Syndrome

Treatment depends on severity, cause, and the patient’s overall condition. Mild CRS may require observation, fever control, hydration, and lab monitoring. Severe CRS may require intensive care. The goal is to calm harmful inflammation without completely shutting down the immune response that may be fighting cancer or infection.

Supportive Care

Supportive care is the foundation of CRS treatment. This may include fever reducers, IV fluids, oxygen therapy, close monitoring of blood pressure and oxygen saturation, and treatment for nausea, pain, or diarrhea. If blood pressure remains low, vasopressor medications may be needed. If breathing worsens, patients may need high-flow oxygen, noninvasive ventilation, or mechanical ventilation.

Because CRS can mimic infection, doctors may start antibiotics while checking cultures and lab results. This is not because antibiotics treat CRS itself, but because missing sepsis would be a very bad plot twist.

Tocilizumab and IL-6 Blockade

Tocilizumab is an IL-6 receptor blocker commonly used for severe or life-threatening CRS related to CAR T-cell therapy. IL-6 is one of the major inflammatory signals involved in many CRS cases. By blocking its receptor, tocilizumab can reduce fever, improve blood pressure, and calm systemic inflammation in appropriate patients.

Timing matters. Tocilizumab is usually given when CRS reaches certain severity thresholds, such as persistent fever with low blood pressure or oxygen needs. Treatment decisions are guided by oncology protocols, the specific immunotherapy used, and the patient’s condition.

Corticosteroids

Corticosteroids such as dexamethasone may be used when CRS is severe, does not respond adequately to other treatment, or occurs with neurologic toxicity. Steroids broadly reduce inflammation. In cancer immunotherapy, clinicians balance the benefits of calming inflammation with the concern that too much immune suppression could reduce anti-cancer activity, although modern protocols use steroids when clinically necessary.

Other Immunomodulators

Some patients may receive other immune-targeting medications, such as anakinra, which blocks interleukin-1 activity, or other agents depending on the clinical scenario. These treatments are usually handled by specialists familiar with CRS, immunotherapy complications, and critical care.

CRS and COVID-19: What Is the Connection?

COVID-19 is caused by SARS-CoV-2, a virus that can range from mild respiratory illness to life-threatening disease. In severe cases, the immune response can become dysregulated. Instead of producing a controlled defense, the body may generate excessive inflammation in the lungs and bloodstream. This can contribute to acute respiratory distress syndrome, low oxygen levels, blood clotting abnormalities, shock, and organ failure.

During the early pandemic, “cytokine storm” became a popular phrase. It was useful because it helped explain why some patients worsened even after the viral phase seemed to be shifting. However, researchers later showed that severe COVID-19 inflammation is complicated. It is not simply “too many cytokines” in every patient. Viral replication, endothelial injury, immune exhaustion, clotting pathways, and underlying health conditions can all play a role.

Still, the CRS framework helped doctors and researchers evaluate anti-inflammatory treatments. Corticosteroids became a major part of care for hospitalized COVID-19 patients requiring oxygen. In selected severe or critical cases with systemic inflammation, guidelines have recommended adding immunomodulators such as tocilizumab, sarilumab, or baricitinib, usually along with corticosteroids. These decisions depend on oxygen needs, timing, inflammatory markers, contraindications, and the patient’s risk of secondary infection.

COVID-19 Symptoms That Need Urgent Attention

Most people with COVID-19 do not develop cytokine storm-like illness. However, urgent medical care is important if symptoms suggest worsening oxygen levels or systemic illness. Warning signs may include trouble breathing, persistent chest pain or pressure, bluish lips or face, confusion, inability to stay awake, severe weakness, or oxygen levels below the range recommended by a healthcare provider.

People at higher risk for severe COVID-19, including older adults and those with certain chronic medical conditions, should seek medical advice early after testing positive. Antiviral treatment works best when started early in eligible patients, before severe inflammation develops. Waiting until the immune system has thrown a full furniture-flipping tantrum is not the ideal strategy.

Can Cytokine Release Syndrome Be Prevented?

CRS cannot always be prevented, especially when it is tied to strong immunotherapy. However, cancer centers use several strategies to reduce risk and catch it early. These may include step-up dosing for certain drugs, premedication, inpatient monitoring, patient education, early lab testing, and rapid access to tocilizumab or steroids when needed.

For COVID-19, prevention focuses on reducing the risk of severe disease. Vaccination, early testing, prompt antiviral treatment for eligible high-risk patients, masking in high-risk settings, ventilation, and staying home when sick can all reduce the chance of serious illness. Good prevention is not flashy, but neither is a seat belt, and seat belts have an excellent résumé.

Living Through CRS: What Patients and Caregivers Should Know

For patients receiving CAR T-cell therapy or other immune-based cancer treatments, CRS can be frightening because it often appears suddenly. A person may feel fine after infusion and then develop fever, chills, body aches, or dizziness days later. The most important practical step is preparation. Patients should know who to call, what temperature threshold matters, which hospital to go to, and whether they need to avoid driving or staying far from the treatment center during the monitoring period.

Caregivers play a major role because CRS can affect energy, blood pressure, and mental clarity. Someone with a high fever may not be the best judge of whether they are “probably fine.” A caregiver can track temperature, notice confusion, help communicate symptoms, and make sure emergency instructions are followed. Think of the caregiver as the project manager for a body that has temporarily become a dramatic group project.

Patients should also keep a treatment card or medication list available. Emergency clinicians need to know if someone recently received CAR T-cell therapy, a bispecific antibody, or another immunotherapy. This information can change the entire approach to care.

Experience-Based Perspective: What CRS Can Feel Like and How to Navigate It

People who go through CRS often describe it less like a single symptom and more like a sudden system-wide crash. One moment, the main concern may be getting through cancer treatment or recovering from an infection. Then fever arrives, followed by chills, exhaustion, racing heart, or the unsettling feeling that the body has hit the emergency broadcast button. Even mild CRS can feel intense because inflammation affects the whole person, not just one organ.

In real-life care settings, the first emotional hurdle is often uncertainty. Is this expected? Is it dangerous? Is it infection? Is the cancer treatment working too well? Is COVID-19 getting worse? The answer may not be obvious at home, and that is exactly why medical teams give strict call instructions. A fever after immunotherapy is not a “wait and see for three days” situation. It is a “call the team now and let them decide” situation.

Another common experience is surprise at how quickly symptoms can change. A patient may start with fever and fatigue, then develop dizziness when standing, shortness of breath while walking to the bathroom, or unusual confusion. These changes matter. Blood pressure and oxygen levels are not personality traits; they are vital signs. When they shift, clinicians need to know.

For caregivers, the experience can be equally stressful. Watching someone become feverish, weak, or confused after a treatment that was supposed to help can feel emotionally upside down. A practical caregiver plan can reduce panic. Keep the oncology phone number visible. Know the emergency department recommended by the treatment team. Write down the date of infusion or diagnosis. Track temperature, oxygen readings if instructed, medications, and symptom changes. Bring the patient’s treatment documents to the hospital.

For COVID-19-related hyperinflammation, the experience may be different. Some people worsen after several days of illness, especially when breathing becomes harder or oxygen levels drop. A pulse oximeter may help certain high-risk patients monitor oxygen at home if their clinician recommends it, but numbers should never replace medical judgment. Shortness of breath, confusion, chest pain, or bluish lips require urgent attention even if someone is tired of hospitals, tired of tests, and deeply committed to pretending everything is fine.

Recovery from CRS varies. Some patients improve quickly after supportive care or tocilizumab. Others need ICU care and a longer recovery period. After the acute episode, fatigue can linger. Patients may need follow-up labs, medication adjustments, and monitoring for neurologic symptoms or organ effects. It is normal to feel shaken afterward. A serious inflammatory episode can be physically and emotionally exhausting.

The most useful mindset is respectful urgency. CRS is not a reason to fear every immunotherapy or panic over every fever, but it is a reason to take instructions seriously. Modern cancer centers and hospitals are much better at recognizing and treating CRS than they were when early immunotherapies first emerged. The playbook has improved. The key is getting the right team involved early.

Conclusion

Cytokine release syndrome is a powerful reminder that the immune system is both a defender and, occasionally, an overenthusiastic security guard tackling the wrong person in the lobby. CRS happens when cytokines surge and trigger body-wide inflammation. It is most commonly associated with CAR T-cell therapy and other immunotherapies, but severe infections such as COVID-19 can also involve cytokine storm-like inflammation.

The most important symptoms include fever, chills, fatigue, fast heartbeat, low blood pressure, breathing difficulty, confusion, and signs of organ stress. Treatment depends on severity and may include monitoring, fluids, oxygen, vasopressors, tocilizumab, corticosteroids, antibiotics while infection is being evaluated, and ICU support when needed. In COVID-19, anti-inflammatory treatment is reserved for specific hospitalized patients, especially those needing oxygen and showing signs of systemic inflammation.

CRS can be serious, but it is also increasingly recognized and treatable. Patients and caregivers should know the warning signs, follow medical instructions closely, and seek help early. When the immune system gets too loud, the right medical team can help turn down the volume before the speakers blow.